Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and/or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise an identified amount or concentration of a processed Morinda citrifolia product or an active ingredient there from, as obtained from the Indian Mulberry plant.

Inventors: Claude Jarakae Jensen, Afa Kehaati Palu, Stephen P. Story, Summer Jensen, Chen Su
Current U.S. Classification: 424/769; 424/777

View patent at USPTO
Search USPTO Assignment Database
Download USPTO Public PAIR data

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US8025910May 10, 2007Sep 27, 2011Tahitian Noni International, Inc.Method and composition for administering bioactive compounds derived from Morinda citrifolia

Claims

1-67. (canceled)

68. A formulation for decreasing the proliferation of human colon adenocarcinoma cells comprising:

a processed Morinda citrifolia product present in an amount between about 0.01 and 100 percent by weight of the composition; and

quercetin.

69. The formulation of claim 68, wherein said processed Morinda citrifolia product comprises Morinda citrifolia fruit juice.

70. The formulation of claim 68, wherein said processed Morinda citrifolia product comprises Morinda citrifolia puree juice.

71. The formulation of claim 68, wherein said processed Morinda citrifolia product comprises Morinda citrifolia puree juice concentrate.

72. The formulation of claim 68, wherein said processed Morinda citrifolia product comprises Morinda citrifolia fruit juice concentrate.

73. The formulation of claim 68, wherein said processed Morinda citrifolia product comprises Morinda citrifolia dietary fiber.

74. The formulation of claim 68, wherein said processed Morinda citrifolia product of said naturaceutical formulation further comprises an active ingredient Quercetin present in an amount between about 0.1 and 10 percent by weight.

75. The formulation of claim 68, wherein said processed Morinda citrifolia product is present in an amount between about 0.01 and 100 percent by weight.

76. The formulation of claim 74, wherein said processed Morinda citrifolia product further comprises Rutin.

77. The formulation of claim 75, wherein said Rutin is present in an amount between about 0.1 and 10 percent by weight.

78. The formulation of claim 68, wherein said naturaceutical is administered orally.

79. The formulation of claim 68, wherein said naturaceutical is administered transdermally to said infected area.

80. The formulation of claim 68, wherein said naturaceutical is administered intravenously.

81. The formulation of claim 68, wherein said naturaceutical is administered systemically.